{"id":"W4408979331","doi":"10.1016/s1556-0864(25)00290-4","title":"95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Basilea Pharmaceutica; Astellas Pharma; Eisai; Castle Biosciences; Pfizer; Moderna; Boston Pharmaceuticals; Agios Pharmaceuticals; Eisai Canada; BeiGene; Mirati Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; Servier; Gilead Sciences; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Internal medicine; Cancer; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003630814,0.0004699881,0.001006528,0.0002169905,0.0002443404,0.0005454375,0.0003525808,0.0005281795,0.003591196],"category_scores_gemma":[0.0006488051,0.0002366957,0.0007685284,0.0002907454,0.0002504003,0.0005004479,0.000266773,0.001206727,0.0006695537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007699446,"about_ca_system_score_gemma":0.0006486375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001555609,"about_ca_topic_score_gemma":0.005129125,"domain_scores_codex":[0.9997751,0.0000593376,0.0000197145,0.00004906928,0.00002890221,0.00006790198],"domain_scores_gemma":[0.9998136,0.00003163575,0.00003183258,0.000007047992,0.000009811856,0.0001061444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5843532,0.005012797,0.06717871,0.001121157,0.00261792,0.001380464,0.0002251092,0.003516525,0.03155583,0.0006638176,0.01464047,0.287734],"study_design_scores_gemma":[0.1813121,0.2565731,0.5035701,0.0005252421,0.004615161,0.004747367,0.0003409797,0.006463124,0.01093403,0.0009758808,0.02977186,0.0001710261],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904398,0.00410967,0.0001412928,0.0006935817,0.0002153784,0.0001197397,0.0005795606,0.00006691336,0.003634211],"genre_scores_gemma":[0.99686,0.0007689436,0.000249819,0.0003386436,0.00006681536,0.00005549774,0.0006022342,0.000005971794,0.001052075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003591196,"threshold_uncertainty_score":0.01201379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008133498182003375,"score_gpt":0.3821783505372515,"score_spread":0.3740448523552481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}